CTOs on the Move

Deciphera

www.deciphera.com

 
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the effectiveness of many cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. Deciphera has developed a diverse pipeline of drug candidates designed to improve outcomes for ...
  • Number of Employees: 100-250
  • Annual Revenue: $500M-1 Billion
  • www.deciphera.com
  • 500 Totten Pond Road 6th Floor
    Waltham, MA USA 02451
  • Phone: 781.209.6400

Executives

Name Title Contact Details
Senthil Gopal
 Director of Cyber Security Profile
Elizabeth Ruhl
 Senior Director, IT Governance, Risk, and Compliance - Information Security Profile
Stephen Aschettino
 Vice President and Chief Information Officer Profile
Stephen Ruddy
 Chief Technical Officer Profile

Similar Companies

Sanofi

Sanofi SA is a French multinational pharmaceutical company headquartered in Paris, France, as of 2013 the worlds fifth-largest by prescription sales.

PCI Synthesis

PCI Synthesis is a custom chemical manufacturer of new chemical entities (NCEs), generic APIs, and other specialty chemical products.

Johnson Matthey Pharmaceutical - West Deptford

Johnson Matthey Pharmaceutical - West Deptford is a Paulsboro, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Good Samaritan Health Center of Gwinnett

The Good Samaritan Health Center of Gwinnett is a non-profit medical clinic whose mission is to demonstrate the love of Christ by providing low-cost primary care, dental care, and disease management services for uninsured residents of the north metro A...

Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.